Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAUSE: 3BNC117-LS-J and 10-1074-LS-J in ART-treated Adults with HIV During ATI
NCT06031272Phase 1Completed
- Start
- May 2024
- Primary completion
- Oct 2025
- Modality
- Anti-infectious Disease mAbs
- Countries
- 3
01
Overview
Phase 1, randomised trial in human immunodeficiency virus infection (HIV) comparing 3BNC117-LS-J + 10-1074-LS-J with Placebo (2 arms). Primary endpoints: Occurrence of a Grade ≥3 or higher systemic AE or any AE leading to premature study or treatment discontinuation at 48 weeks and Viral suppression at 24 weeks. Started May 2024; status: completed.
02
Drugs
Teropavimabzinlirvimab
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06031272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031272.